Topline data from two late-stage studies presented at the San Antonio Breast Cancer Symposium suggest that GlaxoSmithKline's Tykerb used in combination with Roche's Herceptin and chemotherapy produced a stronger response in patients with HER2-positive breast cancer than either drug alone.
Reference Articles
Glaxo's Tykerb lags Herceptin in pre-surgery study - (Forexpros)
Data from Tykerb investigational Phase III studies in neo-adjuvant HER2-positive breast cancer presented at breast cancer symposium - (GlaxoSmithKline)
GlaxoSmithKline presents data from Tykerb Phase III studies - (Morningstar)
Drug combo helps women with early breast cancer - (The Washington Post)
**published in "First Word"
No comments:
Post a Comment